Lessons from approved oligonucleotide therapies (e.g., for SMA and DMD) and their potential in cardiometabolic, inflammatory, and oncology indications

Innovations in extrahepatic delivery, crossing the blood-brain barrier, and improving cellular uptake for broader therapeutic applications

Addressing clinical trial design, safety profiling, and cost-effectiveness to drive the adoption of oligonucleotide drugs in larger patient populations